reports
- LOIC WOLF
Reworld Media: 1 director
A director at Reworld Media bought 20,000 shares at 1.588EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
- LOIC WOLF
- LOIC WOLF
- LOIC WOLF
- LOIC WOLF
- LOIC WOLF
- LOIC WOLF
- LOIC WOLF
- LOIC WOLF
- LOIC WOLF
- LOIC WOLF
- Andreas Riemann
- Charlotte Vaisse
- Marc Lavaud
ODDO BHF Small & MIDCAP MORNING NEWS - 07/12/2023 Date Performance sin...
Although we retain our Neutral rating and DCF based PT of € 1.15 per share, which is based on the current and future Accoya operations, there are scenarios in which additional value can be created, although a strategic partner for Tricoya UK is required. For now, we assume that the company will continue to defer making a go/no go decision about the Tricoya project and will focus on optimising Accoya operations in the Netherlands and completing the Accoya USA project without further de...
- Andreas Riemann
- Charlotte Vaisse
- Marc Lavaud
ODDO BHF Small & MIDCAP MORNING NEWS - 12/07/2023 Date Performance dep...
Although we retain our Neutral rating and DCF based PT of € 1.15 per share, which is based on the current and future Accoya operations, there are scenarios in which additional value can be created, although a strategic partner for Tricoya UK is required. For now, we assume that the company will continue to defer making a go/no go decision about the Tricoya project and will focus on optimising Accoya operations in the Netherlands and completing the Accoya USA project without further de...
- Damien Choplain
- Oussema Denguir
Theranexus : € 3.1m fund raise
>Financial visibility extended to Q4 2024e - Theranexus carried out a capital increase of around € 3.1m via the issue of 2.4 million new shares at a 25.8% discount to the closing price on 10 July 2023 for an actual price of € 1.28/share on a non-diluted basis. As part of this transaction, US foundation BBDF (Beyond Batten Disease Foundation) acquired an 11.6% stake in the capital. BBDF and four other investors whose names were not disclosed represent around 71.2% of t...
- Damien Choplain
- Oussema Denguir
Theranexus : Levée de fonds de 3.1 M€
>Visibilité financière étendue jusqu’au T4 2024e - Theranexus a réalisé une augmentation de capital de c. 3.1 M€ au travers de l’émission de 2.4 M d’actions au prix de 1.28 €, soit une décote de 25.8% par rapport au cours de clôture du 10 juillet 2023. Dans le cadre de cette opération, la fondation américaine BBDF (Beyond Batten Disease Foundation) est entrée au capital à hauteur de 11.6%. BBDF et 4 autres investisseurs dont les noms ne sont pas communiqués représente...
- Team Pharma
ODDO : Un secteur en besoin de financement
La performance boursière du secteur lors de ce début 2023 a été de nouveau extrêmement hétérogène. Que ce soit en Europe ou aux Etats-Unis, le contexte macroéconomique et les difficultés de financement de certains acteurs ont conduit à privilégier les plus grosses capitalisations de la Biotech. Un rebond des opérations M&A se matérialise enfin ce qui devrait revigorer un secteur apathique. Les éléments moteurs ou freinant restent de vigueur à savoir, la clinique et la visibilité ...
EVT EVOTEC SE
TNG TRANSGENE SA
A1XAEB QUANTUM GENOMICS
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
ALCLS CELLECTIS SA
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
POXEL POXEL SA
COPN COSMO PHARMACEUTICALS NV
ALVAL VALBIOTIS SA
ALTHX THERANEXUS SA
DMP DERMAPHARM HOLDING SE
MOR MORPHOSYS AG
MEDCL MEDINCELL SA
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
PA8K PAION AG
- Team Pharma
ODDO : A sector in need of financing
Sector share performances at the start of 2023 were again extremely mixed. In both Europe and the US, the macroeconomic context and the financing difficulties faced by certain players led investors to prefer the largest biotech capitalisations. M&A deals are picking up at last, which should revive a lacklustre sector. The drivers and obstacles still apply, namely clinical results and financial visibility. For the sake of greater contrast in our target prices, we applied a beta of...
EVT EVOTEC SE
TNG TRANSGENE SA
A1XAEB QUANTUM GENOMICS
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
ALCLS CELLECTIS SA
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
POXEL POXEL SA
COPN COSMO PHARMACEUTICALS NV
ALVAL VALBIOTIS SA
ALTHX THERANEXUS SA
DMP DERMAPHARM HOLDING SE
MOR MORPHOSYS AG
MEDCL MEDINCELL SA
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
PA8K PAION AG
- Mohamed Kaabouni
- Mohamed Kaabouni
- Nicolas Royot
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.